Advances in the treatment of Raynaud’s phenomenon

Advances in the treatment of Raynaud’s phenomenon

Terri L LevienDrug Information Pharmacist and Clinical Associate Professor, College of Pharmacy, Washington State University Spokane, WA, USAAbstract: Raynaud’s phenomenon is a common condition characterized by vasospasm of the digital arteries and resulting cyanosis and redness. It of...

Full description

Bibliographic Details
Main Author: Terri L Levien
Format: Article
Language:English
Published: Dove Medical Press 2010-03-01
Series:Vascular Health and Risk Management
Online Access:http://www.dovepress.com/advances-in-the-treatment-of-raynaudrsquos-phenomenon-a4074
id doaj-c41a719904ba4a0eb00917e93bdf4047
record_format Article
spelling doaj-c41a719904ba4a0eb00917e93bdf40472020-11-24T23:46:02ZengDove Medical PressVascular Health and Risk Management1176-63441178-20482010-03-012010default167177Advances in the treatment of Raynaud’s phenomenonTerri L LevienTerri L LevienDrug Information Pharmacist and Clinical Associate Professor, College of Pharmacy, Washington State University Spokane, WA, USAAbstract: Raynaud’s phenomenon is a common condition characterized by vasospasm of the digital arteries and resulting cyanosis and redness. It often does not require pharmacologic management, but in some cases symptoms are severe and pharmacologic management is necessary. Calcium channel blockers are often used first-line, but in some patients are ineffective. Patients with severe symptoms or intolerance to available therapies have prompted exploration of alternative therapies, including endothelin antagonists, phosphodiesterase-5 inhibitors, antioxidants, newer vasodilators, statins, and botulinum toxin. These newer therapies provide the focus for this review.Keywords: Raynaud, iloprost, bosentan, phosphodiesterase-5 inhibitors http://www.dovepress.com/advances-in-the-treatment-of-raynaudrsquos-phenomenon-a4074
collection DOAJ
language English
format Article
sources DOAJ
author Terri L Levien
spellingShingle Terri L Levien
Advances in the treatment of Raynaud’s phenomenon
Vascular Health and Risk Management
author_facet Terri L Levien
author_sort Terri L Levien
title Advances in the treatment of Raynaud’s phenomenon
title_short Advances in the treatment of Raynaud’s phenomenon
title_full Advances in the treatment of Raynaud’s phenomenon
title_fullStr Advances in the treatment of Raynaud’s phenomenon
title_full_unstemmed Advances in the treatment of Raynaud’s phenomenon
title_sort advances in the treatment of raynaud’s phenomenon
publisher Dove Medical Press
series Vascular Health and Risk Management
issn 1176-6344
1178-2048
publishDate 2010-03-01
description Terri L LevienDrug Information Pharmacist and Clinical Associate Professor, College of Pharmacy, Washington State University Spokane, WA, USAAbstract: Raynaud’s phenomenon is a common condition characterized by vasospasm of the digital arteries and resulting cyanosis and redness. It often does not require pharmacologic management, but in some cases symptoms are severe and pharmacologic management is necessary. Calcium channel blockers are often used first-line, but in some patients are ineffective. Patients with severe symptoms or intolerance to available therapies have prompted exploration of alternative therapies, including endothelin antagonists, phosphodiesterase-5 inhibitors, antioxidants, newer vasodilators, statins, and botulinum toxin. These newer therapies provide the focus for this review.Keywords: Raynaud, iloprost, bosentan, phosphodiesterase-5 inhibitors
url http://www.dovepress.com/advances-in-the-treatment-of-raynaudrsquos-phenomenon-a4074
work_keys_str_mv AT terrillevien advancesinthetreatmentofraynaudamprsquosphenomenon
_version_ 1725494970647838720

Similar Items